What is AB2 Bio?
AB2 Bio is a clinical-stage biotechnology firm focused on developing novel therapies for severe systemic autoinflammatory diseases, including rare conditions with critical unmet medical needs. The company's lead candidate, Tadekinig alfa, is a proprietary IL-18 binding protein that has demonstrated clinical proof-of-concept in three life-threatening orphan autoinflammatory indications. Beyond its core focus, AB2 Bio is also exploring Tadekinig alfa's potential in oncology and for managing cytokine release syndrome associated with COVID-19. Strategically located within the Innovation Park at the Ecole Polytechnique Federale de Lausanne (EPFL) in Switzerland, AB2 Bio is positioned at the forefront of biopharmaceutical innovation.
How much funding has AB2 Bio raised?
AB2 Bio has raised a total of $21M across 1 funding round:
Series B
$21M
Series B (2016): $21M, investors not publicly disclosed
What's next for AB2 Bio?
With a major enterprise-level funding context and a recent strategic investment, AB2 Bio is poised for significant advancement in its late-stage clinical pipeline. The company's focus on Tadekinig alfa for rare autoinflammatory diseases, coupled with its exploration in oncology and COVID-19 related conditions, suggests a strategic expansion of its therapeutic reach. This substantial backing will likely accelerate clinical trials, support regulatory submissions, and potentially facilitate market entry for its innovative treatments, solidifying its position in the biopharmaceutical landscape.
See full AB2 Bio company page
